Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?
---- Acknowledgments ----
We are grateful to Bennett Erickson and Addison Wood for expert help with data preparation and analysis, and to Laura Panattoni and session participants at the June, 2014 American Society of Heath Economics meetings for valuable comments on an earlier version of the paper. We also thank Moneil Abu Speitan, Mike Augusteijn, Sebastian Bauhoff, Rena Conti, Abe Dunn, Robert Drake, Randy Ellis, Robert Feinberg, Ray Hartman, Laura Hatfield, C. Scott Hemphill, Haiden Huskamp, Anupam Jena, Tim Layton, R. Forrest McCluer, Eileen Morrison, Joseph Newhouse, Ketan Patel, Renee Rushnawitz, Julie Shi and James Sigel for insightful comments and suggestions. Responsibility for the analyses and conclusions expressed here is the authors' own. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.
---- Disclosure of Financial Relationships for Keith M. Drake ----
Keith Drake received support for professional development from Greylock McKinnon Associates. No other external funding was provided to any of the authors for this research.